Cargando…

Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: a case report

The complete pathological response after primary chemotherapy could represent an important prognostic factor in patients affected by colorectal liver metastases. In recent studies, increasing complete pathological response seems to be correlated with longer overall survival periods and it is recogni...

Descripción completa

Detalles Bibliográficos
Autores principales: Malavasi, Norma, Ponti, Giovanni, Depenni, Roberta, Bertolini, Federica, Zironi, Sandra, Luppi, Gabriele, Conte, Pier Franco
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2731036/
https://www.ncbi.nlm.nih.gov/pubmed/19660136
http://dx.doi.org/10.1186/1756-8722-2-35
_version_ 1782170924714295296
author Malavasi, Norma
Ponti, Giovanni
Depenni, Roberta
Bertolini, Federica
Zironi, Sandra
Luppi, Gabriele
Conte, Pier Franco
author_facet Malavasi, Norma
Ponti, Giovanni
Depenni, Roberta
Bertolini, Federica
Zironi, Sandra
Luppi, Gabriele
Conte, Pier Franco
author_sort Malavasi, Norma
collection PubMed
description The complete pathological response after primary chemotherapy could represent an important prognostic factor in patients affected by colorectal liver metastases. In recent studies, increasing complete pathological response seems to be correlated with longer overall survival periods and it is recognized as an important prognostic factor in patients treated with pre-operative chemotherapy. The correlation of radiological information on residual neoplastic disease after neoadjuvant treatment, obtained with CT and PET, has to be evaluated; in fact the complete disappearance of liver metastasis on radiological imaging does not always mean a complete disappearance of tumor tissue on histological examination; when it is documented with surgical procedures and confirmed by pathologist's examination, we can consider the complete pathological response. In recent years the addition of monoclonal antibodies to conventional chemotherapy may further increase the proportion of patients referred for surgery; bevacizumab before surgery has been shown to be feasible and safe, although concerns still exist regarding possible post-surgical and wound healing complications or bleeding. The limitation of the radiologic assessment of response as a surrogate for pathological response is even more relevant when antiangiogenic treatments are used. Excellent responses to bevacizumab-containing regimens do occur and referral to surgical oncology is a crucial step for documentation of complete pathological response.
format Text
id pubmed-2731036
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27310362009-08-24 Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: a case report Malavasi, Norma Ponti, Giovanni Depenni, Roberta Bertolini, Federica Zironi, Sandra Luppi, Gabriele Conte, Pier Franco J Hematol Oncol Case Report The complete pathological response after primary chemotherapy could represent an important prognostic factor in patients affected by colorectal liver metastases. In recent studies, increasing complete pathological response seems to be correlated with longer overall survival periods and it is recognized as an important prognostic factor in patients treated with pre-operative chemotherapy. The correlation of radiological information on residual neoplastic disease after neoadjuvant treatment, obtained with CT and PET, has to be evaluated; in fact the complete disappearance of liver metastasis on radiological imaging does not always mean a complete disappearance of tumor tissue on histological examination; when it is documented with surgical procedures and confirmed by pathologist's examination, we can consider the complete pathological response. In recent years the addition of monoclonal antibodies to conventional chemotherapy may further increase the proportion of patients referred for surgery; bevacizumab before surgery has been shown to be feasible and safe, although concerns still exist regarding possible post-surgical and wound healing complications or bleeding. The limitation of the radiologic assessment of response as a surrogate for pathological response is even more relevant when antiangiogenic treatments are used. Excellent responses to bevacizumab-containing regimens do occur and referral to surgical oncology is a crucial step for documentation of complete pathological response. BioMed Central 2009-08-06 /pmc/articles/PMC2731036/ /pubmed/19660136 http://dx.doi.org/10.1186/1756-8722-2-35 Text en Copyright © 2009 Malavasi et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Malavasi, Norma
Ponti, Giovanni
Depenni, Roberta
Bertolini, Federica
Zironi, Sandra
Luppi, Gabriele
Conte, Pier Franco
Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: a case report
title Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: a case report
title_full Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: a case report
title_fullStr Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: a case report
title_full_unstemmed Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: a case report
title_short Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: a case report
title_sort complete pathological response in a patient with multiple liver metastases from colon cancer treated with folfox-6 chemotherapy plus bevacizumab: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2731036/
https://www.ncbi.nlm.nih.gov/pubmed/19660136
http://dx.doi.org/10.1186/1756-8722-2-35
work_keys_str_mv AT malavasinorma completepathologicalresponseinapatientwithmultiplelivermetastasesfromcoloncancertreatedwithfolfox6chemotherapyplusbevacizumabacasereport
AT pontigiovanni completepathologicalresponseinapatientwithmultiplelivermetastasesfromcoloncancertreatedwithfolfox6chemotherapyplusbevacizumabacasereport
AT depenniroberta completepathologicalresponseinapatientwithmultiplelivermetastasesfromcoloncancertreatedwithfolfox6chemotherapyplusbevacizumabacasereport
AT bertolinifederica completepathologicalresponseinapatientwithmultiplelivermetastasesfromcoloncancertreatedwithfolfox6chemotherapyplusbevacizumabacasereport
AT zironisandra completepathologicalresponseinapatientwithmultiplelivermetastasesfromcoloncancertreatedwithfolfox6chemotherapyplusbevacizumabacasereport
AT luppigabriele completepathologicalresponseinapatientwithmultiplelivermetastasesfromcoloncancertreatedwithfolfox6chemotherapyplusbevacizumabacasereport
AT contepierfranco completepathologicalresponseinapatientwithmultiplelivermetastasesfromcoloncancertreatedwithfolfox6chemotherapyplusbevacizumabacasereport